摘要
在发展日新月异的心血管介入治疗领域,有关的抗凝治疗也随之迅速发展,而其中抗血小板药物的发展速度属于较快的一类,第59届ACC年会中公布了多项抗血小板药物的临床研究结果,部分临床试验可谓突破了介入治疗的一些瓶颈。
In the ever-changing field of cardiovascular intervention,the concerned anticoagulant therapy achieved fast development,and development of anti-platelet drugs is in fast track,results of multiple clinical studies of anti-platelet drugs were publicized in the American College of Cardiology(ACC) 59th Annual Scientif ic Session,and some clinical trials broke the bottlenecks in cardiovascular intervention.
出处
《中国处方药》
2010年第4期37-39,共3页
Journal of China Prescription Drug
